| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström macroglobulinemia (WM) |
| 10 Nov 2026 | 10-Q |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program |
| 13 Aug 2026 | 10-Q |
| 04 Aug 2026 | SCHEDULE 13G |
| 10 Jul 2026 |
Form 4/A: Loren Stefan, Consultant
Granted 15,000 Stock option (right to buy) |
| 10 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this 2021 Stock Incentive Plan (the “Plan”) is to encourage and enable officers and employees of, and other persons providing services to, Cellectar Biosciences, Inc. (the “Company”) and its Subsidiaries (as defined below)... |
| 08 Jul 2026 |
Form 4: Kolean Chad J, CFO
Granted 92,000 Stock option (right to buy) |
| 08 Jul 2026 |
Form 4: Driscoll Frederick W, Director
Granted 25,000 Stock option (right to buy) |
| 08 Jul 2026 |
Form 4: Chanan-Khan Asher, Director
Granted 25,000 Stock option (right to buy) |
| 08 Jul 2026 |
Form 4: Caruso James V, Director
Granted 250,000 Stock option (right to buy) |
| 08 Jul 2026 |
Form 4: Gu Andrew, Director
Granted 25,000 Stock option (right to buy) |
| 08 Jul 2026 |
Form 4: Longcor Jarrod, Chief Operating Officer
Granted 118,000 Stock option (right to buy) |
| 08 Jul 2026 |
Form 4: Swirsky Douglas J, Director
Granted 37,500 Stock option (right to buy) |
| 08 Jul 2026 |
Form 4: Neis John, Director
Granted 25,000 Stock option (right to buy) |
Loading...